Polymorphism in the Promoter Region of Let-7 and Response to Doxorubicin Treatment in Egyptian Hepatocellular Carcinoma
El-gedawy, A., Ali, S., Tabashy, R., Abd El-hady, A., Hassan, Z. (2020). Polymorphism in the Promoter Region of Let-7 and Response to Doxorubicin Treatment in Egyptian Hepatocellular Carcinoma. EKB Journal Management System, 4(2), 56-62. doi: 10.21608/aprh.2020.22581.1098
Asmaa El-gedawy; Sahar Ali; Reda Tabashy; Abd El-wahab Abd El-hady; Zeinab Hassan. "Polymorphism in the Promoter Region of Let-7 and Response to Doxorubicin Treatment in Egyptian Hepatocellular Carcinoma". EKB Journal Management System, 4, 2, 2020, 56-62. doi: 10.21608/aprh.2020.22581.1098
El-gedawy, A., Ali, S., Tabashy, R., Abd El-hady, A., Hassan, Z. (2020). 'Polymorphism in the Promoter Region of Let-7 and Response to Doxorubicin Treatment in Egyptian Hepatocellular Carcinoma', EKB Journal Management System, 4(2), pp. 56-62. doi: 10.21608/aprh.2020.22581.1098
El-gedawy, A., Ali, S., Tabashy, R., Abd El-hady, A., Hassan, Z. Polymorphism in the Promoter Region of Let-7 and Response to Doxorubicin Treatment in Egyptian Hepatocellular Carcinoma. EKB Journal Management System, 2020; 4(2): 56-62. doi: 10.21608/aprh.2020.22581.1098

Polymorphism in the Promoter Region of Let-7 and Response to Doxorubicin Treatment in Egyptian Hepatocellular Carcinoma

Journal of Advanced Pharmacy Research
Article 2, Volume 4, Issue 2, April 2020, Page 56-62  XML PDF (270.08 K)
Document Type: Research Article
DOI: 10.21608/aprh.2020.22581.1098
View on SCiNiTO View on SCiNiTO
Authors
Asmaa El-gedawy1; Sahar Ali email 2; Reda Tabashy3; Abd El-wahab Abd El-hady4; Zeinab Hassan2
1Operation Pharmacy, Helwan General Hospital, Helwan, Egypt
2Biochemistry Department, Faculty of Pharmacy, Helwan University, Egypt
3Diagnostic and interventional radiology, National Cancer Institute, Cairo University, Egypt
4Department of Cancer Biology, National Cancer Institute, Cairo University
Abstract
Background: polymorphisms in different miRNAs lately are found to have potential to be biomarkers for HCC susceptibility, but the results still inconsistent. Objective: This study was conducted to explore the potential role and clinical significance of rs 10877887 polymorphisms in the promoters of let-7 family and risk of HCC susceptibility, in addition to response to doxorubicin treatment in Egyptian patients. Patients and methods: We genotyped the single nucleotide polymorphism (SNP) in 100 patients with HCC and 50 healthy controls. Analysis of the rs10877887 was done using polymerase chain reaction-restriction fragment length polymorphism assay. Results: We found that the rs 10877887 genotype distribution and allele frequency did not associated neither with increased risk of developing HCC (adjusted OR =0.7178, 95% CI, [0.4409 – 1.1687], p1=[0.1825] P>0.05) nor with the response to doxorubicin treatment (adjusted OR = 1.1874, 95% CI, 0.6683.-2.1096, P = 0.5581). Conclusion: These findings indicate that the rs10877887 CC/CT may not play a role as a risk factor for the development of HCC. Also, it cannot be used to detect the response of Egyptian patients to doxorubicin treatment.
Keywords
Doxorubicin; Egyptian patients; Hepatocellular carcinoma; Let-7; Polymorphism
Statistics
Article View: 255
PDF Download: 386